The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Seufert et al., N Engl J Med 345(26):1883-1888 December 27, 2001.

Correspondence
PreviousPrevious
Volume 346:1748-1749 May 30, 2002 Number 22
NextNext

Octreotide for Tumor-Induced Osteomalacia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Seufert, J.
-Related Article
by Seufert, J.
-PubMed Citation
To the Editor: Seufert et al. (Dec. 27 issue)1 describe a man with tumor-induced (oncogenic) osteomalacia, in which the subcutaneous administration of octreotide abolished renal tubular phosphate wasting. The authors suggest that in patients who cannot undergo surgery, phosphate wasting may be relieved by treatment with somatostatin analogues, provided that the tumor expresses somatostatin receptors. We believe that this statement is a misleading generalization. We observed a case of oncogenic osteomalacia in which total-body octreotide scintigraphy detected the tumor. We therefore intravenously administered octreotide at a dose of 600 µg per day for six days — a dose in the . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.